Neogen® Introduces Igenity® BCHF to Help Industry Mitigate Bovine Congestive Heart Failure Risk
Neogen (NASDAQ: NEOG) has launched Igenity BCHF, a groundbreaking genomic test designed to assess the genetic risk of Bovine Congestive Heart Failure (BCHF) in cattle. The test provides a 1-to-10 scoring system, where 1 indicates the lowest risk and 10 the highest risk of disease development, with each score decrease representing approximately 3.5% lower expected incidence rate.
The innovative test aims to help producers manage BCHF risk within their herds, produce lower-risk feeder calves, and reduce economic losses. BCHF is identified as a significant threat affecting both young calves on pasture and late-fed cattle. According to Dr. Victor Pedrosa, Director of Technical Genomics and Innovation, the test results indicate the percentage of BCHF risk an animal might pass to its progeny.
Neogen (NASDAQ: NEOG) ha lanciato Igenity BCHF, un test genomico innovativo progettato per valutare il rischio genetico di Insufficienza Cardiaca Congestizia Bovina (BCHF) nel bestiame. Il test fornisce un sistema di punteggio da 1 a 10, dove 1 indica il rischio più basso e 10 il rischio più alto di sviluppo della malattia, con ogni diminuzione del punteggio che rappresenta circa il 3,5% in meno del tasso di incidenza atteso.
Il test innovativo mira ad aiutare i produttori a gestire il rischio di BCHF all'interno dei loro allevamenti, a produrre vitelli da ingrasso a rischio minore e a ridurre le perdite economiche. La BCHF è identificata come una minaccia significativa che colpisce sia i vitelli giovani al pascolo che il bestiame alimentato in ritardo. Secondo il Dr. Victor Pedrosa, Direttore della Genomica Tecnica e dell'Innovazione, i risultati del test indicano la percentuale di rischio di BCHF che un animale potrebbe trasmettere alla sua progenie.
Neogen (NASDAQ: NEOG) ha lanzado Igenity BCHF, una prueba genética innovadora diseñada para evaluar el riesgo genético de Insuficiencia Cardíaca Congestiva Bovina (BCHF) en el ganado. La prueba proporciona un sistema de puntuación de 1 a 10, donde 1 indica el riesgo más bajo y 10 el riesgo más alto de desarrollo de la enfermedad, con cada disminución en la puntuación representando aproximadamente un 3.5% menos de tasa de incidencia esperada.
La prueba innovadora tiene como objetivo ayudar a los productores a gestionar el riesgo de BCHF dentro de sus rebaños, producir terneros de engorde de menor riesgo y reducir las pérdidas económicas. La BCHF se identifica como una amenaza significativa que afecta tanto a los terneros jóvenes en pastoreo como al ganado alimentado en último momento. Según el Dr. Victor Pedrosa, Director de Genómica Técnica e Innovación, los resultados de la prueba indican el porcentaje de riesgo de BCHF que un animal podría transmitir a su descendencia.
Neogen (NASDAQ: NEOG)은 소의 울혈성 심부전(BCHF)의 유전적 위험을 평가하기 위해 설계된 혁신적인 유전학 테스트 Igenity BCHF를 출시했습니다. 이 테스트는 1에서 10까지의 점수 체계를 제공하며, 1은 가장 낮은 위험을 나타내고 10은 질병 발병의 가장 높은 위험을 나타냅니다. 각 점수의 감소는 약 3.5%의 예상 발생률 감소를 나타냅니다.
이 혁신적인 테스트는 생산자가 자신의 떼에서 BCHF 위험을 관리하고, 저위험 송아지를 생산하며, 경제적 손실을 줄이는 데 도움을 주는 것을 목표로 합니다. BCHF는 젊은 송아지와 후기 사료를 먹는 소 모두에게 영향을 미치는 중요한 위협으로 식별됩니다. 기술 유전체학 및 혁신 담당 이사인 빅토르 페드로사는 테스트 결과가 동물이 자손에게 유전할 수 있는 BCHF 위험의 비율을 나타낸다고 말합니다.
Neogen (NASDAQ: NEOG) a lancé Igenity BCHF, un test génomique révolutionnaire conçu pour évaluer le risque génétique d'Insuffisance Cardiaque Congestive Bovine (BCHF) chez les bovins. Le test fournit un système de notation de 1 à 10, où 1 indique le risque le plus bas et 10 le risque le plus élevé de développement de la maladie, chaque diminution de point représentant environ 3,5 % de réduction du taux d'incidence attendu.
Ce test innovant vise à aider les producteurs à gérer le risque de BCHF au sein de leurs troupeaux, à produire des veaux d'engraissement à risque réduit et à diminuer les pertes économiques. La BCHF est identifiée comme une menace importante affectant à la fois les jeunes veaux en pâturage et les bovins nourris tardivement. Selon le Dr Victor Pedrosa, directeur de la génomique technique et de l'innovation, les résultats du test indiquent le pourcentage de risque de BCHF qu'un animal pourrait transmettre à sa descendance.
Neogen (NASDAQ: NEOG) hat Igenity BCHF eingeführt, einen bahnbrechenden genomischen Test, der entwickelt wurde, um das genetische Risiko von Bovin Congestive Heart Failure (BCHF) bei Rindern zu bewerten. Der Test bietet ein Bewertungssystem von 1 bis 10, wobei 1 das geringste Risiko und 10 das höchste Risiko für die Entwicklung der Krankheit anzeigt, wobei jeder Rückgang des Scores ungefähr eine um 3,5 % niedrigere erwartete Inzidenzrate repräsentiert.
Der innovative Test zielt darauf ab, Produzenten dabei zu helfen, das BCHF-Risiko innerhalb ihrer Herden zu managen, risikoärmere Fütterungs-Kälber zu erzeugen und wirtschaftliche Verluste zu reduzieren. BCHF wird als eine bedeutende Bedrohung identifiziert, die sowohl junge Kälber auf der Weide als auch spät gefütterte Rinder betrifft. Laut Dr. Victor Pedrosa, Direktor für Technische Genomik und Innovation, zeigen die Testergebnisse den Prozentsatz des BCHF-Risikos, den ein Tier an seine Nachkommen weitergeben könnte.
- First-of-its-kind genomic test for BCHF risk assessment
- Quantifiable risk assessment with 3.5% reduction per score decrease
- Potential to reduce economic losses from BCHF-related mortality
- None.
Insights
The launch of Igenity® BCHF represents a strategic move into the bovine health diagnostics market. The test's ability to predict BCHF risk with a quantifiable
The product addresses a critical market gap in preventative cattle health management. While the immediate revenue impact may be modest relative to Neogen's
Simple explanation: Think of this like a genetic early warning system for heart problems in cattle. Just as human genetic tests can warn about health risks, this tool helps farmers identify which cows might develop heart issues before they show any symptoms, potentially saving thousands of dollars per herd in prevented losses.
The technical specifications of Igenity® BCHF position it as a pioneering diagnostic tool in livestock genomics. The 1-10 scoring system demonstrates sophisticated genomic analysis capabilities, likely leveraging advanced SNP identification and quantitative trait locus mapping. This validates Neogen's R&D competency in developing proprietary genetic markers.
The test's commercial potential is enhanced by its integration into Neogen's existing Igenity® platform, suggesting minimal additional infrastructure investment for deployment. The scalability of genomic testing, combined with recurring revenue potential from regular herd screening, creates an attractive business model. This launch reinforces Neogen's position in the growing
Simple explanation: Imagine having a crystal ball that can look into a cow's DNA and predict its future heart health. This test is like having that crystal ball and farmers will likely pay regularly to use it because it helps them make better breeding decisions and avoid costly losses.
Bovine Congestive Heart Failure (BCHF) stands as a significant threat to cattle health and productivity, and this genomic test provides a new opportunity for improved selection for heart health. Testing with Igenity BCHF assesses an animal's genetic predisposition for BCHF, scored on a 1-to-10 scale. Ranging from 1 (lowest risk) to 10 (highest risk of disease development), each decreased score on the scale as an approximately
"Igenity BCHF is a revolutionary genomic test designed to assess an animal's genetic predisposition to heart failure," says Victor Pedrosa, Ph.D., Director of Technical Genomics and Innovation at Neogen. "The test results directly correlate with the percentage of BCHF risk an animal carries and could pass on to their progeny, serving as a genetic indicator of the likelihood of disease development."
BCHF presents a growing threat to the health and productivity of all segments of the cattle industry, from young calves on the pasture to late-fed cattle. Igenity BCHF provides producers with the opportunity to more effectively manage the risk of BCHF within their herd, confidently produce feeder calves that will have a lower risk of mortality from BCHF in a feedlot setting, and decrease economic losses attributed to BCHF.
"When we look at the impact of Igenity BCHF on the industry, it is helping to genetically quantify the risk for bovine congestive heart failure and progress herds away from this growing cattle health and welfare concern," says Kirk Ramsey, DVM, Professional Services Veterinarian with Neogen. "Igenity BCHF is the first genomic test of its kind and is the first step in capturing the reason why congestive heart failure is occurring in these young calves and late-fed cattle."
To learn more about Igenity BCHF, visit neogen.com/igenity-beef or contact your Neogen representative.
About Neogen
Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.
Media Contact
View original content to download multimedia:https://www.prnewswire.com/news-releases/neogen-introduces-igenity-bchf-to-help-industry-mitigate-bovine-congestive-heart-failure-risk-302355664.html
SOURCE Neogen Corporation
FAQ
What is the scoring range for Neogen's new Igenity BCHF test?
How does Neogen's Igenity BCHF test benefit cattle producers?
What types of cattle can be affected by BCHF according to NEOG's announcement?
When did Neogen (NEOG) launch the Igenity BCHF test?
